A.V. DUBOVAYA¹, N.A. USENKO¹, S.A. YULDASHEVA², N.V. BURYAK¹

 ¹M. Gorky Donetsk State Medical University, Donetsk

²V.K. Gusak Institute of Emergency and Reconstructive Surgery, Donetsk

 Contact details:

Dubovaya A.V. — MD, Professor, Head of the Department of Pediatrics No. 3

Address: 16 prospekt Ilyicha, 283003 Donetsk, Russian Federation, tel.: +7-949-398-97-85, e-mail: dubovaya_anna@mail.ru

Studying approaches to the treatment of acute lymphoblastic leukemia (ALL) in children is relevant because this oncohematological pathology is the most common in the pediatric population. Modern chemotherapy protocols provide for the differentiated use of cytostatics, taking into account the immunophenotypic and molecular genetic characteristics of tumor cells. This makes it possible to achieve a five-year survival rate of more than 90% of pediatric patients with ALL. However, the ALL forms resistant to chemotherapy, high-risk patients, and relapses force improvements in treatment methods. The above circumstances necessitate a comprehensive analysis of modern scientific data on the treatment of acute lymphoblastic leukemia in children, systematize current data on pathogenetic mechanisms and their impact on the choice of therapeutic tactics, as well as analyze the effectiveness of existing treatment protocols, taking into account the stratification of patients by risk groups and the molecular genetic characteristics of tumor cells. The implementation of the tasks set will make it possible to systematize modern approaches to the treatment of acute lymphoblastic leukemia in children and identify the most promising areas for further research.

Key words: acute lymphoblastic leukemia, children, cytostatics, chemotherapy, drug toxicity, bone marrow transplantation.

REFERENCES

1. Volkova A.R. Childhood malignant neoplasms and their accounting: global and domestic trends. Rossiyskiy zhurnal detskoy gematologii i onkologii (RZhDGiO), 2020, vol. 7, no. 3, pp. 64–69 (in Russ.).
2. Liu L., Villavicencio F., Yeung D. et al. National, regional, and global causes of mortality in 5–19-year-olds from 2000 to 2019: a systematic analysis. The Lancet. Global Health, 2022, vol. 10 (3), pp. e337–e347.
3. Suprun R.N., Rumyantseva Yu.V., Bydanov O.I. et al. Acute lymphoblastic leukemia in children with Down syndrome: experience of the Moscow-Berlin group. Voprosy gematologii / onkologii i immunopatologii v pediatrii, 2021, no. 1, pp. 14–26 (in Russ.).
4. Maschan M.A., Myakova N.V. Acute lymphoblastic leukemia in children. Onkogematologiya, 2006, no. 1–2, pp. 50–63 (in Russ.).
5. Wertheim G. Infant acute leukemia. Clin. Lab. Med, 2021, vol. 41 (3), pp. 541–550.
6. Inaba H. Advances in the diagnosis and treatment of pediatric acute lymphoblastic leukemia. J. Clin. Med, 2021, vol. 10 (9), p. 1926.
7. Mukhina V.A., Ushakova I.A., Zueva T.V. Acute lymphoblastic leukemia in children. Mezhdunarodnyy studencheskiy nauchnyy vestnik, 2020, no. 1, p. 15 (in Russ.).
8. Paina O.V., Semenova E.V., Markova I.V. et al. Modern concepts of the therapy of acute leukemia in children under 1 year old. Rossiyskiy zhurnal detskoy gematologii i onkologii, 2019, vol. 6, no. 2, pp. 11–19 (in Russ.).
9. Abaji R., Gagné V., Xu C.J. et al. Whole-exome sequencing identified genetic risk factors for asparaginase-related complications in childhood ALL patients. Oncotarget, 2017, vol. 8 (27), rr. 43752–43767.
10. Gabay P.G., Dronova S.A. New order in pediatric oncology and hematology: too many questions. Voprosy sovremennoy pediatrii, 2021, vol. 20, no. 4, pp. 327–332 (in Russ.).
11. Deak D., Gorcea-Andronic N., Sas V. et al. A narrative review of central nervous system involvement in acute leukemias. Ann. Transl. Med, 2021, vol. 9 (1), r. 68.
12. Gabitova N.Kh., Zhdanova S.I., Cherezova I.N. et al. A case of congenital lymphoblastic leukemia in a newborn child. Rossiiyskiiy vestnik perinatologii i pediatrii, 2020, vol. 65, no. 5, pp. 204–208 (in Russ.).
13. Popov A.M., Verzhbitskaya T.Yu., Zueva E.E. et al. Results of external quality control of acute lymphoblastic leukemia diagnostics by flow cytometry. Onkogematologiya, 2016, vol. 11, no. 3, pp. 68–75 (in Russ.).
14. Ol’khovskiy I.A., Komina A.V., Stolyar M.A., Gorbenko A.S. Molecular genetic disorders in acute leukemia as a basis for developing diagnostic tests. Laboratornaya sluzhba, 2020, vol. 9, no. 4, pp. 26–45 (in Russ.).
15. Pinkel D. History and development of total therapy for acute lymphocytic leukemia. Leukemia Res.: Adv. Cell Biol. Treat, 1983, pp. 189–201.
16. Aleskerova G.A., Shervashidze M.A., Popa A.V. et al. Results of treatment of acute lymphoblastic leukemia in children according to the ALL IC-BFM 2002 protocol. Onkopediatriya, 2016, vol. 3, no. 4, pp. 302–308 (in Russ.).
17. Brown P.A., Shah B., Advani A. et al. Acute lymphoblastic leukemia, version 2.2021, NCCN clinical practice guidelines in oncology. J. Natl. Compr. Canc. Netw, 2021, vol. 19 (9), rr. 1079–1109.
18. Tomizawa D., Miyamura T., Imamura T. et al. A riskstratified therapy for infants with acute lymphoblastic leukemia: a report from the JPLSG MLL10 trial. Blood, 2020, vol. 136 (16), rr. 1813–1823.
19. Balashov D.N., Shelikhova L.N., Maschan M.A. Hematopoietic stem cell transplantation: indications, types of transplantation, donor choice. Voprosy gematologii / onkologii i immunopatologii v pediatrii, 2022, vol. 21, no. 2, pp. 131–135 (in Russ.).
20. Liu Y.F., Wang B.Y., Zhang W.N. Genomic profiling of adult and pediatric B-cell acute lymphoblastic leukemia. EBioMed, 2016, no. 8, rr. 173–183.
21. Valiev T.T., Shervashide M.A., Osipova I.V. et al. Protocol ALL IC-ВFМ 2002: results of treatment of acute lymphoblastic leukemia in children within the framework of a multicenter clinical trial. Clinical oncohematology. Fundamental’nye issledovaniya i klinicheskaya praktika, 2022, vol. 15, no. 2, pp. 119–129 (in Russ.).
22. Klinicheskie rekomendatsii. Ostryy limfoblastnyy leykoz (Deti) [Clinical guidelines. Acute lymphoblastic leukemia (Children)], available at: https://cr.minzdrav.gov.ru/view-cr/529_1 (accessed on: 22.12.2024).
23. Rumyantseva Yu.V., Karachunskiy A.I., Aleynikova O.V. et al. Efficiency of the ALL-MB-2002 protocol in children with acute lymphoblastic leukemia. Terapevticheskiy arkhiv, 2010, no. 7, pp. 11–20 (in Russ.).
24. Halsey C., Buck G., Richards S. et al. The impact of therapy for childhood acute lymphoblastic leukaemia on intelligence quotients; results of the risk-stratified randomized central nervous system treatment trial MRC UKALL XI. J. Hematol. Oncol, 2011, no. 4, rr. 42.
25. Relling M.V., Hancock M.L., Boyett J.M. et al. Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia. Blood, 1999, vol. 93 (9), rr. 2817–2823.
26. Hutchinson R.J., Gaynon P.S., Sather H. et al. Intensification of therapy for children with lower-risk acute lymphoblastic leukemia: long-term follow-up of patients treated on Children’s Cancer Group Trial 1881. J Clin. Oncol, 2003, vol. 21 (9), rr. 1790–1797.
27. Litvinov D.V., Karelin A.F., Romanova K.I. et al. Treatment of acute lymphoblastic leukemia in children: current capabilities and unsolved problems. Doktor.Ru, 2015, vol. 10, no. 111, rr. 30–37 (in Russ.).
28. Suprun R.N., Rumyantseva Yu.V., Bydanov O.I. et al. Acute lymphoblastic leukemia in children with Down syndrome: a comparative analysis of treatment results according to the ALL-MB 2008 and ALL-MB 2015 protocols. Rossiyskiy zhurnal detskoy gematologii i onkologii (RZhDGiO), 2022, vol. 9, no. 3, pp. 12–31 (in Russ.).
29. Silverman L.B., Stevenson K.E., O’Brien J.E. et al. Long-term results of Dana-Farber Cancer Institute ALL Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1985–2000). Leukemia, 2010, vol. 24 (2), pp. 320–333.
30. Pehlivan K.C., Duncan B.B., Lee D.W. CAR-T Cell therapy for acute lymphoblastic leukemia: transforming the treatment of relapsed and refractory disease. Curr. Hematol. Malig. Rep, 2018, vol. 13 (5), rr. 396–406.
31. Shifrin Yu.A. Justification of a rational method for pharmacoeconomic evaluation of the effectiveness of using a monoclonal antibody drug in the treatment of acute lymphoblastic leukemia in children and adolescents. Vestnik biomeditsina i sotsiologiya, 2022, vol. 7, no. 1, pp. 13–21 (in Russ.).
32. Delea T.E., Zhang X., Amdahl J. et al. Cost effectiveness of blinatumomab versus inotuzumab ozogamicin in adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia in the United States. PharmacoEconomics, 2019, vol. 37 (9), pp. 1177–1193.
33. Bondarenko S.N., Parovichnikova E.N., Maschan A.A. et al. Blinatumomab in the treatment of acute lymphoblastic leukemia: A Russian multicenter study. Klinicheskaya onkogematologiya, 2019, vol. 12, no. 2, pp. 145–153 (in Russ.).
34. Markova I.V., Bondarenko S.N., Paina O.V. et al. Features of response to blinatumomab and inotuzumab ozogamicin therapy in patients with relapse/refractory B-cells acute lymphoblastic leukemia in real clinical practice. Cell Ther. Transplant, 2020, vol. 9 (1), rr. 47–52.
35. Hunger S.P., Mullighan C.G. Acute lymphoblastic leukemia in children. N Engl. J. Med, 2015, vol. 373 (16), rr. 1541–1552.
36. Geyer M.B., Hsu M., Devlin S.M. et al. Overall survival among older US adults with ALL remains low despite modest improvement since 1980: SEER analysis. Blood, 2017, vol. 129 (13), rr. 1878–1881.
37. Beznos O.A., Grivtsova L.Yu., Popa A.V. et al. Definition of minimal residual disease in B-lineage acute lymphoblastic leukemia using EuroFlow approaches. Klinicheskaya onkogematologiya, 2017, vol. 10, no. 2, pp. 58–68 (in Russ.).